Jasper Therapeutics (JSPR) Competitors $2.93 -0.02 (-0.68%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$2.98 +0.05 (+1.71%) As of 08/22/2025 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock JSPR vs. SXTC, CRBU, CCCC, TVGN, SLS, ENTA, LFVN, ACTU, NKTX, and NVCTShould you be buying Jasper Therapeutics stock or one of its competitors? The main competitors of Jasper Therapeutics include China SXT Pharmaceuticals (SXTC), Caribou Biosciences (CRBU), C4 Therapeutics (CCCC), Tevogen Bio (TVGN), SELLAS Life Sciences Group (SLS), Enanta Pharmaceuticals (ENTA), Lifevantage (LFVN), Actuate Therapeutics (ACTU), Nkarta (NKTX), and Nuvectis Pharma (NVCT). These companies are all part of the "pharmaceutical products" industry. Jasper Therapeutics vs. Its Competitors China SXT Pharmaceuticals Caribou Biosciences C4 Therapeutics Tevogen Bio SELLAS Life Sciences Group Enanta Pharmaceuticals Lifevantage Actuate Therapeutics Nkarta Nuvectis Pharma China SXT Pharmaceuticals (NASDAQ:SXTC) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment. Do insiders & institutionals have more ownership in SXTC or JSPR? 5.0% of China SXT Pharmaceuticals shares are owned by institutional investors. Comparatively, 79.9% of Jasper Therapeutics shares are owned by institutional investors. 4.0% of China SXT Pharmaceuticals shares are owned by insiders. Comparatively, 4.6% of Jasper Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has more risk & volatility, SXTC or JSPR? China SXT Pharmaceuticals has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500. Comparatively, Jasper Therapeutics has a beta of 2.7, meaning that its stock price is 170% more volatile than the S&P 500. Is SXTC or JSPR more profitable? China SXT Pharmaceuticals' return on equity of 0.00% beat Jasper Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets China SXT PharmaceuticalsN/A N/A N/A Jasper Therapeutics N/A -172.28%-128.34% Which has stronger valuation & earnings, SXTC or JSPR? China SXT Pharmaceuticals has higher revenue and earnings than Jasper Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioChina SXT Pharmaceuticals$1.74M104.69-$3.30MN/AN/AJasper TherapeuticsN/AN/A-$71.27M-$6.01-0.49 Do analysts rate SXTC or JSPR? Jasper Therapeutics has a consensus price target of $28.75, suggesting a potential upside of 881.23%. Given Jasper Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Jasper Therapeutics is more favorable than China SXT Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China SXT Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Jasper Therapeutics 0 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.60 Does the media prefer SXTC or JSPR? In the previous week, Jasper Therapeutics had 8 more articles in the media than China SXT Pharmaceuticals. MarketBeat recorded 9 mentions for Jasper Therapeutics and 1 mentions for China SXT Pharmaceuticals. China SXT Pharmaceuticals' average media sentiment score of 1.95 beat Jasper Therapeutics' score of -0.69 indicating that China SXT Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment China SXT Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Jasper Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Negative SummaryJasper Therapeutics beats China SXT Pharmaceuticals on 7 of the 12 factors compared between the two stocks. Get Jasper Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JSPR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding JSPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JSPR vs. The Competition Export to ExcelMetricJasper TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$44.01M$3.11B$5.81B$9.76BDividend YieldN/A2.23%4.39%4.06%P/E Ratio-0.4921.0031.3626.05Price / SalesN/A209.44387.8788.42Price / CashN/A44.5038.0259.36Price / Book1.888.129.536.60Net Income-$71.27M-$54.72M$3.26B$265.65M7 Day Performance-5.79%2.62%2.14%2.00%1 Month Performance-6.39%3.25%3.22%0.46%1 Year Performance-84.81%10.82%30.18%18.88% Jasper Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JSPRJasper Therapeutics2.9063 of 5 stars$2.93-0.7%$28.75+881.2%-84.8%$44.01MN/A-0.4920SXTCChina SXT Pharmaceuticals0.7397 of 5 stars$1.59-0.6%N/A-77.9%$185.64M$1.74M0.0090News CoveragePositive NewsShort Interest ↑Gap DownCRBUCaribou Biosciences2.7172 of 5 stars$1.87-5.6%$6.67+256.5%-16.3%$184.38M$9.99M0.00100News CoverageAnalyst UpgradeCCCCC4 Therapeutics1.2097 of 5 stars$2.86+16.3%$8.00+179.7%-60.7%$175.08M$35.58M0.00150High Trading VolumeTVGNTevogen Bio3.9828 of 5 stars$0.96+1.6%$10.00+937.6%+61.4%$174.39MN/A0.003News CoverageEarnings ReportSLSSELLAS Life Sciences Group2.8731 of 5 stars$1.73+6.1%$7.00+304.6%+44.7%$171.63M$1M0.0010ENTAEnanta Pharmaceuticals3.5209 of 5 stars$8.17+2.1%$21.67+165.2%-32.5%$171.02M$67.64M0.00160LFVNLifevantage3.6984 of 5 stars$13.69+1.5%$30.50+122.8%+52.1%$169.81M$222.35M19.84260News CoveragePositive NewsUpcoming EarningsACTUActuate TherapeuticsN/A$8.25+1.6%$20.50+148.5%+3.5%$166.22MN/A0.0010News CoverageAnalyst DowngradeAnalyst RevisionNKTXNkarta1.8463 of 5 stars$2.35+0.9%$13.60+478.7%-55.5%$165.49MN/A0.00140NVCTNuvectis Pharma3.7203 of 5 stars$6.45+0.3%$15.33+137.7%-3.2%$163.69MN/A0.008Positive News Related Companies and Tools Related Companies China SXT Pharmaceuticals Alternatives Caribou Biosciences Alternatives C4 Therapeutics Alternatives Tevogen Bio Alternatives SELLAS Life Sciences Group Alternatives Enanta Pharmaceuticals Alternatives Lifevantage Alternatives Actuate Therapeutics Alternatives Nkarta Alternatives Nuvectis Pharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:JSPR) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump’s “new dollar” could shock Americans"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredTrump’s SHOCKING Plan to Create MASSIVE Wealth for AmericansJames Altucher says Donald Trump just made a move so surprising, it could go down as the most lucrative presid...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jasper Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jasper Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access